Zimmer Biomet Holdings, Inc.
HealthcareNYSE:ZBH · New York Stock Exchange
+$1.44 today
Vol 1.30M · Avg 2.32M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$8.4B of revenue converted into $761.3M of net income for the selected period. Gross margin is 70.2% and net margin is 9.1%, showing how much revenue survives after costs and taxes. EPS is $3.85, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.2B +7.2% | $7.7B +3.8% | $7.4B +6.5% | $6.9B +1.6% | $6.8B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.2B +44.2% | $2.2B +5.2% | $2.1B +3.2% | $2.0B +3.0% | $2.0B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $5.1B -7.6% | $5.5B +3.3% | $5.3B +7.9% | $4.9B +1.1% | $4.9B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.6% -9.8pp | 71.5% -0.4pp | 71.8% +0.9pp | 70.9% -0.4pp | 71.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $458.5M +4.8% | $437.4M -4.6% | $458.7M +13.0% | $406.0M -6.8% | $435.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $3.3B +11.0% | $2.9B +3.2% | $2.8B +2.8% | $2.8B -2.9% | $2.8B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.7B -11.7% | $4.2B +4.2% | $4.0B -4.5% | $4.2B +5.4% | $4.0B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.1B +9.8% | $996.3M +4.7% | $951.7M +2.7% | $926.4M -1.2% | $937.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | $2.2B -1.5% | $2.3B +1.4% | $2.2B +48.5% | $1.5B -9.1% | $1.6B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 26.9% -2.4pp | 29.3% -0.7pp | 30.0% +8.5pp | 21.5% -2.6pp | 24.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.4B +6.0% | $1.3B +0.6% | $1.3B +83.5% | $696.3M -19.1% | $860.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 16.5% -0.2pp | 16.7% -0.5pp | 17.3% +7.2pp | 10.0% -2.6pp | 12.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $292.8M +34.3% | $218.0M +8.3% | $201.2M +22.1% | $164.8M -20.9% | $208.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$531.4M -113.3% | -$249.1M -18.4% | -$210.4M +28.1% | -$292.8M +19.0% | -$361.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $830.8M -19.9% | $1.0B -2.9% | $1.1B +164.5% | $403.5M -19.1% | $499.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 10.1% -3.4pp | 13.5% -0.9pp | 14.4% +8.6pp | 5.8% -1.5pp | 7.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $125.7M -4.3% | $131.4M +211.4% | $42.2M -62.4% | $112.3M +109.9% | $53.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | $705.2M -22.0% | $903.8M -11.7% | $1.0B +342.5% | $231.4M -42.4% | $401.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 8.6% -3.2pp | 11.8% -2.1pp | 13.8% +10.5pp | 3.3% -2.5pp | 5.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $4 -20.0% | $4 -9.4% | $5 +346.4% | $1 -43.0% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $4 -19.9% | $4 -9.2% | $5 +343.6% | $1 -42.4% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $198.0M -2.5% | $203.1M -2.7% | $208.7M -0.4% | $209.6M +0.5% | $208.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $198.7M -2.6% | $203.9M -2.8% | $209.7M -0.3% | $210.3M -0.0% | $210.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DexCom, Inc.
NASDAQ:DXCM
$28.76B
Illumina, Inc.
NASDAQ:ILMN
$24.54B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.26B
Waters Corporation
NYSE:WAT
$23.17B
United Therapeutics Corporation
NASDAQ:UTHR
$23.02B
Quest Diagnostics Incorporated
NYSE:DGX
$22.44B
Incyte Corporation
NASDAQ:INCY
$21.79B
Labcorp Holdings Inc.
NYSE:LH
$21.67B
STERIS plc
NYSE:STE
$20.25B
Smith & Nephew plc
NYSE:SNN
$12.97B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ZBH generate?
Zimmer Biomet Holdings, Inc. (ZBH) reported $8.23B of revenue in fiscal 2025.
Is ZBH profitable?
Zimmer Biomet Holdings, Inc. (ZBH) reported $705.20M of net income, with a net margin of 8.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.